BACKGROUND: Despite advances in novel therapeutics, supportive care, and postremission therapy, the outcome of high-risk and elderly patients as well as those with relapsed/refractory acute myeloid leukemia (AML) remains poor. There is likely still room for improvement through optimizing conventional chemotherapy. PATIENTS AND METHODS: Through a pharmacy database search we identified all patients with AML treated at Washington University with cladribine-based regimens. RESULTS: Twenty-four patients were identified that were treated with 2 cladribine-based regimens: CLAG (cladribine [5 mg/m2 days 1-5], cytarabine [2 g/m2 days 1-5] and granulocyte colony-stimulating factor [G-CSF; 300 microg subcutaneously (s.c.) days 0-5]) and CLAM (cladribine [5 mg/m2 days 1-5], cytarabine [2 g/m2 days 1-5], G-CSF [300 mg s.c. days 0-5] and mitoxantrone [10 mg/m2 days 1-3]). Complete responses were achieved in 53% of patients given induction chemotherapy and 44% of those given salvage chemotherapy. The regimens were well tolerated with minimal extramedullary toxicity. CONCLUSION: These data suggest that cladrabine-based regimens should be further explored in both the salvage and first-line setting and might offer an attractive backbone on which to add novel therapies.
BACKGROUND: Despite advances in novel therapeutics, supportive care, and postremission therapy, the outcome of high-risk and elderly patients as well as those with relapsed/refractory acute myeloid leukemia (AML) remains poor. There is likely still room for improvement through optimizing conventional chemotherapy. PATIENTS AND METHODS: Through a pharmacy database search we identified all patients with AML treated at Washington University with cladribine-based regimens. RESULTS: Twenty-four patients were identified that were treated with 2 cladribine-based regimens: CLAG (cladribine [5 mg/m2 days 1-5], cytarabine [2 g/m2 days 1-5] and granulocyte colony-stimulating factor [G-CSF; 300 microg subcutaneously (s.c.) days 0-5]) and CLAM (cladribine [5 mg/m2 days 1-5], cytarabine [2 g/m2 days 1-5], G-CSF [300 mg s.c. days 0-5] and mitoxantrone [10 mg/m2 days 1-3]). Complete responses were achieved in 53% of patients given induction chemotherapy and 44% of those given salvage chemotherapy. The regimens were well tolerated with minimal extramedullary toxicity. CONCLUSION: These data suggest that cladrabine-based regimens should be further explored in both the salvage and first-line setting and might offer an attractive backbone on which to add novel therapies.
Authors: David G J Cucchi; Costa Bachas; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Zinia J Kwidama; Gerrit J Schuurhuis; Yehuda G Assaraf; Valérie de Haas; Gertjan J L Kaspers; Jacqueline Cloos Journal: Cancers (Basel) Date: 2020-05-15 Impact factor: 6.639
Authors: David Martínez-Cuadrón; Josefina Serrano; José Mariz; Cristina Gil; Mar Tormo; Pilar Martínez-Sánchez; Eduardo Rodríguez-Arbolí; Raimundo García-Boyero; Carlos Rodríguez-Medina; Carmen Martínez-Chamorro; Marta Polo; Juan Bergua; Eliana Aguiar; María L Amigo; Pilar Herrera; Juan M Alonso-Domínguez; Teresa Bernal; Ana Espadana; María J Sayas; Lorenzo Algarra; María B Vidriales; Graça Vasconcelos; Susana Vives; Manuel M Pérez-Encinas; Aurelio López; Víctor Noriega; María García-Fortes; María C Chillón; Juan I Rodríguez-Gutiérrez; María J Calasanz; Jorge Labrador; Juan A López; Blanca Boluda; Rebeca Rodríguez-Veiga; Joaquín Martínez-López; Eva Barragán; Miguel A Sanz; Pau Montesinos Journal: Cancers (Basel) Date: 2022-06-06 Impact factor: 6.575